Seòmar agus comataidhean

Since November 2021, sentinel surveillance data have been available for mycoplasma pneumoniae in Scotland through the CARI sentinel surveillance programme. In this programme, sentinel GP practices across Scotland recruit and swab patients with symptoms of acute respiratory infection. These samples are all tested for ten respiratory pathogens, including mycoplasma pneumoniae. Enhanced surveillance data, primarily relating to symptoms, are collected by an online questionnaire from patients tested in the programme. Analyses from these data suggest that most infections display as a mild respiratory illness. To date, there have been no deaths in 1280 CARI patients positive for mycoplasma pneumoniae (up to week 7) within 28 days of their test. With the information from CARI, GP providers have been advised that they should consider mycoplasma pneumoniae as part of the differential diagnosis for community-acquired pneumonia cases.

PHS separately analyses data on all microbiology laboratory specimen results across Scotland to identify positive mycoplasma pneumoniae test in hospitals or care homes, or as requested in the community (by GPs). These data are reviewed by PHS and NHS Health Boards to identify any clusters or trends resulting in severe disease that warrant further intervention. To date, no unusual outbreaks or evidence of increased severity of disease has been noted and public health guidance on management of cases/clinical treatment remains unchanged.

The Scottish Government recognises that surveillance is a critical part of our approach to monitoring and managing the spread and prevalence of mycoplasma pneumoniae, Covid-19 and other respiratory infections. Public Health Scotland (PHS) are responsible for delivering Scotland’s National Respiratory Surveillance Plan with the support of the Scottish Government.

As part of PHS’s work, respiratory infection levels, including those of mycoplasma pneumoniae, and their impact are closely monitored throughout the year using various sources of data, including microbiological sampling and laboratory test results from community and hospital settings, NHS 24 calls, primary care consultations, hospital admissions, and mortality by cause. Intelligence generated from the different Scottish surveillance systems, including for mycoplasma pneumoniae, are used to inform proactive measures to prevent spread and ensure timely clinical response.

The National Strategy for Economic Transformation (NSET) announced an Inclusive Business Models review. The review is ongoing and is led by a representative stakeholder group. The independent review group is chaired by Neil McInroy, Global Lead for Community Wealth Building, The Democracy Collaborative and chair of Economic Development Association of Scotland (EDAS).

The review group is drawing on learning from both national and international experience. It is anticipated that the work will complete, with findings and recommendations published, in Spring 2024.

As this is an operational matter for Scottish Water I have asked them to respond. Their reply is as follows:

Scottish Water has published its Improving Urban Waters Routemap ( https://www.scottishwater.co.uk/Help-and-Resources/Document-Hub/Key-Publications/Urban-Waters-Improvements ) which outlines the process to identify and plan future investment for the highest priority Unsatisfactory Intermittent Discharges (UIDs). This planned approached is agreed in conjunction with the environmental regulator SEPA.

Each financial year (Apr-Mar) it reports UID figures within an Annual return to the Water Industry Commission for Scotland (WICS) and as at March 2023 the figure was 776. This number is revised each year as improvement projects address UIDs and on-going studies identify new UIDs. The figure for 2023-24 will be published later this year.

The statutory minimum walking distances set out in legislation are a long-standing feature of our education system and there are no plans to change them. The Scottish Government published guidance for local authorities regarding home to school transport in 2021. The provision of home to school transport is responsibility of local authorities and decisions about changes to eligibility for free school transport are for local authorities to make, subject to the applicable statutory requirements.

All regulated procurements are conducted in accordance with the requirements of the Sustainable Procurement Duty and in accordance with guidance and good practice, including Scottish Procurement Policy Note 3/2022 which provides guidance to support taking account of climate and circular economy considerations in our procurement processes. The sustainable procurement duty within the Procurement Reform (Scotland) Act 2014 (the “Act”) requires public bodies to consider how they can improve the economic, social and environmental wellbeing of the authority’s area, and act in a way to secure improvements identified.

The Act requires authorities to outline in their Annual Procurement Strategy how procurement will deliver local environmental impacts and report progress in their Annual Procurement Reports.

We have developed our centrally-funded, Sustainable Procurement Tools (the “Tools”) to include Climate Literacy eLearning which is mandated for Scottish Procurement and Property Directorate staff.

Opportunities to build sustainability into all frameworks and contracts are identified at strategy stage and embedded throughout the procurement process, highlighting key opportunities which can be assessed as part of our tender evaluation and monitored through ongoing contract management. Environmental objectives include opportunities to reduce emissions, appropriate climate change adaption, use of materials, waste, bio security and bio diversity. Tenderers are also encouraged to offer community benefits which will help to support our climate change objectives and our journey to net zero.

This is an operational matter for ScotRail. The member may wish to contact ScotRail directly.

The Fair Work Working Group (FWWG) continues to explore ways to promote all aspects of fair work across the sector, finding common ground on good fair work practices which will be both meaningful and impactful and will encourage retail businesses to demonstrate their commitment to the Fair Work principles.

New Year's Day trading can be discussed and non-legislative routes explored in relation to the approach on fair work if the FWWG members choose to do so as part of their regular discussions and as they continue to collaborate on the fair work action with the trade unions and industry stakeholders through the Retail Industry Leadership Group.

The Scottish Government has no plans to reinstate the Carers Register in GP practices.

The Carers Register was previously undertaken by practices as part of the Quality and Outcomes Framework (QOF). The requirement for practices to complete the QOF was removed in 2016 and quality planning, improvement and assurance within general practice is now carried out through GP Clusters.

The Scottish Government recognises the vital role played by carers and practices can continue to use markers on their patient registrations to recognise those with caring duties.

NHS Scotland currently offers a whole gene screening panel for hereditary breast and ovarian cancer to test for faults in both BRCA1 and BRCA2 and a range of other target genes. At present, this testing is available to people from specific population groups (including those of Ashkenazi Jewish heritage) if they meet clinical criteria that indicate a higher genetic risk of breast and ovarian cancer.

The Scottish Strategic Network for Genomic Medicine (SSNGM) was established in 2022 to develop a fully considered and sustainable genomic medicine service for Scotland. The SSNGM contains specialist Scottish Genomics Test Advisory Groups (SG-TAG) for both cancer and rare and inherited conditions, whose role is to review and assess the clinical validity and utility of new tests, and changes to the referral criteria for existing tests.

The SSNGM plan to initiate a review of the existing hereditary cancer testing pathways in 2024. This review will include both the referral criteria for our existing genomic test offering and alternative testing methods and will make recommendations via the SG-TAG process.